Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462860 · ClinicalTrials.gov registry record · NA
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
A NA study of Burns and Wound of Skin, sponsored by The Metis Foundation.
- Recruiting
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05462860: Recruiting NA study of Burns and Wound of Skin, sponsored by The Metis Foundation.
NCT05462860 is a NA study of Burns and Wound of Skin that is actively recruiting participants, run by The Metis Foundation. The registered enrollment target is 21 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462860, a NA study of Burns and Wound of Skin, is actively recruiting participants, sponsored by The Metis Foundation.
- RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.
Primary Outcome
The reduction of need for grafting measured by the percentage of subjects who are converting to grafting at 21 ± 3 days after application.
Conditions Studied
Interventions
- OTHER Suprathel®
Study Locations (1)
North Carolina
- North Carolina Jaycee Burn Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2026-06-29 |
| Phase | NA |
What NCT05462860 shows while recruiting
NCT05462860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Burns appearing as the primary indexed condition, and to 1 intervention - of which Suprathel® is the first listed.
NCT05462860 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05462860 about?
NCT05462860 is a clinical study titled "Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds". The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infec...
What is the current status of trial NCT05462860?
This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2024-09-18. Estimated completion is 2026-06-29.
What conditions does trial NCT05462860 study?
This clinical trial studies the following conditions: Burns, Wound of Skin.
What interventions are being tested in trial NCT05462860?
The interventions under investigation include: Suprathel® (OTHER).
Who is sponsoring clinical trial NCT05462860?
This trial is sponsored by The Metis Foundation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462860 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05462860's enrollment target sits among peer trials
21 22nd of 36 higher than 15 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery
RECRUITING · NA
-
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
ACTIVE NOT RECRUITING · NA
-
Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation
ACTIVE NOT RECRUITING · NA
-
Virtual Reality in Burn Pain Management
COMPLETED · NA
-
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
COMPLETED · NA
-
VR for Pain Management During Adult Burn Dressing Change
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI